Skip to main content
Explore URMC

Thomas P. Frye, D.O.

Contact Information

Phone Numbers

Appointment: (585) 275-2838

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Surgery, Urology


Thomas Frye, DO, Assistant Professor of Urology, is a Urologic Oncologist who specializes in minimally invasive urologic oncology (robotic surgery of bladder, prostate, and kidney cancers), advanced open pelvic and retroperitoneal cancer surgery, and detection and management of localized prostate cancer with magnetic resonance imaging (MRI). Dr. Frye is one of only a few providers in the United States who offers High Intensity Focused Ultrasound (HIFU) - personalized treatment of prostate cancer.

Dr. Frye joined UR Medicine Urology after completing a fellowship in Urologic Oncology within The National Cancer Institute at the National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Frye completed his urology residency at Southern Illinois University School of Medicine. He received his doctor of Osteopathy degree from Midwestern University, Chicago College of Osteopathic Medicine, where he was awarded valedictorian of his class.

Dr. Frye has clinical and research interests in prostate cancer. During his fellowship, he worked extensively in optimizing and refining the use of prostate MRIs. Dr. Frye's clinical research interest also includes focal therapy of prostate cancer.

Dr. Frye is licensed to practice medicine in the District of Columbia and state of New York and is a member of the American Urological Association, Society of Urologic Oncology and American Society of Clinical Oncology.

Dr. Frye has clinical expertise in all aspects of general urology with a special emphasis on the following:

- Prostate Cancer
- Bladder Cancer
- Kidney Cancer
- Testicular Cancer
- Penile Cancer
- High Intensity Focused Ultrasound (HIFU)
- Minimally-Invasive Surgery (Robotic and Laparoscopic)
- UroNav Fusion Prostate Biopsy
- Thermotherapies for Renal Cancer




    DO | Midwestern University

    Post-doctoral Training & Residency

    07/01/2014 - 06/30/2016
    Fellowship in Urologic Oncology at National Cancer Institute/National Institute of Health

    06/26/2010 - 06/26/2014
    Residency in Urology at Southern Illinois University School Of Medicine

    07/01/2009 - 06/25/2010
    Internship in Surgery (General Surgery) at Southern Illinois University School Of Medicine

    VIEW ALL expand_more

    Clinical Trials

    Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

    Lead Researcher: Thomas P Frye

    This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.

    View Study Details


    Journal Articles

    Ghazi A, Melnyk R, Hung AJ, Collins J, Ertefaie A, Saba P, Gurung P, Frye T, Rashid H, Wu G, Mottrie A, Costello T, Dasgupta P, Joseph J. "Multi-institutional validation of a Perfused Robot-Assisted Partial Nephrectomy Procedural Simulation platform utilizing clinically relevant objective metrics of simulators (CROMS)." BJU international.. 2020 Sep 16; Epub 2020 Sep 16.

    Gurung PMS, Frye TP, Rashid HH, Joseph JV, Wu G. "Robot-assisted Synchronous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease: a Stepwise Description of Technique." Urology.. 2020 Jun 17; Epub 2020 Jun 17.

    Witthaus MW, Farooq S, Melnyk R, Campbell T, Saba P, Mathews E, Ezzat B, Ertefaie A, Frye TP, Wu G, Rashid H, Joseph JV, Ghazi A. "Incorporation and validation of clinically relevant performance metrics of simulation (CRPMS) into a novel full-immersion simulation platform for nerve-sparing robot-assisted radical prostatectomy (NS-RARP) utilizing three-dimensional printing and hydrogel casting technology." BJU Int. 2020; .

    Books & Chapters

    Chapter Title: Neuropsychology of Genitourinary Malignancies
    Book Title: Neuropsychology of Cancer and Oncology
    Author List: Frye TP, Miller J, Tarter TH
    Published By: Springer Publishing Company 2012




    Thomas Patrick Frye, D.O., UR Medicine Urology